TREK1 channel activation as a new analgesic strategy devoid of opioid adverse effects

Area of Science:

• Pharmacology
• Neuroscience
• Pain Research

Background:

• Opioids are effective analgesics but pose significant risks due to adverse effects and misuse, creating a public health crisis.
• The μ opioid receptor mediates both pain relief and adverse effects, making it difficult to separate these actions.
• The TREK1 potassium channel is implicated in pain relief but not adverse effects, suggesting it as a potential therapeutic target.

Purpose of the Study:

• To investigate whether direct activation of the TREK1 potassium channel could provide pain relief without adverse effects.
• To develop and test a selective TREK1 activator as a potential safer analgesic strategy.

Main Methods:

• Development of a selective TREK1 activator, RNE28.
• Testing RNE28 in rodent models of naive, inflammatory, and neuropathic pain.
• Evaluating RNE28's antinociceptive activity in TREK1 knockout mice and with the TREK1 blocker spadin.
• Assessing RNE28 for opioid-associated adverse effects (respiratory depression, constipation, reward, sedation).

Main Results:

• RNE28 demonstrated significant antinociceptive activity in various pain models.
• The antinociceptive effect of RNE28 was dependent on TREK1 activity, confirmed by knockout and blocker studies.
• RNE28 did not produce respiratory depression, constipation, rewarding effects, or sedation at analgesic doses.

Conclusions:

• Direct TREK1 activation represents a viable strategy for developing novel analgesics.
• TREK1 activators offer a potential opioid-sparing approach to pain management, devoid of common opioid side effects.
• This study provides a proof-of-concept for a new class of safer painkillers targeting the TREK1 channel.